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The subjects comprised 230 men aged 77 ± 10 (range: 50–100) years and 279 women aged 81 ± 10 (50–101) years that visited
the medical department. We examined the relationship between increased serum bilirubin and renal function evaluated by
estimated glomerular filtration rate (eGFR) usingCKD-EPI equationsmodified by a Japanese coefficient. Comparedwith the fourth
quartile in serum bilirubin (1.01–1.97mg/dL), the nonadjusted, age and gender-adjusted, and multivariate-adjusted odds ratios
{95% confidence interval (CI)} of eGFR <60mL/min/1.73m2 for the first quartile in serum bilirubin (0.13–0.50mg/dL) were 2.08
(1.25–3.44), 1.82 (1.07–3.09), and 1.53 (0.83–2.81), respectively. Moreover, compared with the fourth quartile, nonadjusted, age and
gender-adjusted, andmultivariate-adjusted odds ratios (95%CI) of eGFR <45mL/min/1.73m2 for the first quartile were 3.50 (1.95–
6.23), 3.12 (1.72–5.65), and 3.53 (1.71–7.26), respectively.Thedatawere further stratified by gender, age,medication (antihypertensive,
antidyslipidemic, and antidiabetic agents), and prevalence of cardiovascular disease (CVD).The standardized coefficients for eGFR
were significant in all the subgroups other than the prevalence of CVD, and there were significant interactions between the two
groups regarding CVD. Our data demonstrated an independent positive association between serum bilirubin and eGFR among
diabetic patients.
1. Introduction
Serum bilirubin may protect against inflammation, cardio-
vascular disease (CVD), and all-cause mortality in adults
[1, 2]. Moreover, current evidences demonstrate that mildly
elevated serumbilirubinmay confer potent antioxidant prop-
erties, as indicated by its ability to scavenge peroxyl radicals
and to inhibit oxidation of low-density lipoprotein (LDL)
derived lipids [3, 4]. Lots of studies have shown apositive rela-
tionship between serum bilirubin and estimated glomerular
filtration rate (eGFR) [5–9], showing that serum bilirubin
has a potential renoprotective effect. We also demonstrated
an independent positive association between serum bilirubin
and eGFR in both genders among elderly persons [10].
Therefore, it is reasonable to speculate that serum bilirubin
levelsmay be negatively correlatedwith diabetic nephropathy
and renal function among diabetic patients.
Several cross-sectional studies have shown that low
serum bilirubin levels were significantly associated with
decreased eGFR, and negatively associated with diabetic
nephropathy in a hospital-based sample of diabetic patients
[6, 7]. In a cohort of Japanese type 2 diabetic patients,
Mashitani et al. [9, 11] demonstrated that serum bilirubin
levels were prospectively associated with diabetic nephropa-
thy progression, independent of possible confounders. In
contrast, Targher et al. [12] found that serum bilirubin was
negatively associatedwith eGFR, considering serumbilirubin
as a renal risk factor. Thus, a relationship between serum
bilirubin and renal function remains controversial.
We evaluated the relationship of serum bilirubin with
confounding risk factors such as renal function, as well
as hypertension, hyperglycemia, and lipids, using cross-
sectional data from the Nomura study [10].
2. Methods
2.1. Subjects. Patients for this investigation were recruited
among consecutive diabetic patients aged ≥50 years that
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visited the Medical Department of Seiyo Municipal Nomura
Hospital. Patients with serum bilirubin > 2.0mg/dL and
severe cardiorenal (e.g., Gilbert’s syndrome) or nutritional
disorders that would affect blood pressure, lipid, and glucose
metabolism were excluded. Thus, 509 persons were enrolled
in the study. All procedures were approved by the Ethics
Committee of SeiyoMunicipal NomuraHospital, andwritten
informed consent was obtained from each patient.
2.2. Evaluation of Confounding Factors. Information on
demographic characteristics and confounding factors was
collected using clinical files in all cases. Body mass index
(BMI) was calculated by dividing weight (in kilograms) by
the square of the height (in meters). We measured systolic
blood pressure (SBP) and diastolic blood pressure (DBP)
in the right upper arm of patients while in a sedentary
position using a standard sphygmomanometer or an auto-
matic oscillometric blood pressure recorder. Smoking status
was quantified based on daily consumption and duration of
smoking (pack⋅year) irrespective of the difference between
current and past smoking status: never, light (<20 pack⋅year),
moderate (20–39 pack⋅year), and heavy (≥40 pack⋅year).
Total cholesterol (T-C), triglycerides (TG), high-density
lipoprotein cholesterol (HDL-C), fasting plasma glucose
(FPG), creatinine (enzymatic method), uric acid, and serum
bilirubin were measured during a fasting condition within
24 hours after admission. Low-density lipoprotein cholesterol
(LDL-C) level was calculated by the Friedewald formula [13],
and those patients with TG levels ≥400mg/dL were excluded.
eGFR was calculated using CKD-EPI equations modified by
a Japanese coefficient (eGFRCKDEPI): male, Cr ≤ 0.9mg/dL,
141 × (Cr/0.9)−0.411 × 0.993age × 0.813; Cr > 0.9mg/dL,
141 × (Cr/0.9)−1.209 × 0.993age × 0.813; female, Cr ≤ 0.7mg/
dL, 144 × (Cr/0.7)−0.329 × 0.993age × 0.813; Cr > 0.7mg/dL,
144 × (Cr/0.7)−1.209 × 0.993age × 0.813 [14].Histories of anti-
hypertensive, antidyslipidemic, and antidiabetic medication
use were also evaluated. Moreover, ischemic stroke, ischemic
heart disease, and peripheral vascular disease were defined as
CVD.
2.3. Statistical Analysis. All values are expressed as the mean
± standard deviation (SD), unless otherwise specified, and
in the cases of parameters with nonnormal distribution
(such as TG, FPG, and serum bilirubin), the data are shown
as median (interquartile range) values. In all the analyses,
parameters with nonnormal distributions were used after
log-transformation. Statistical analysis was performed using
IBM SPSS Statistics Version 21 (Statistical Package for Social
Science Japan, Inc., Tokyo, Japan). Pearson’s correlations were
calculated in order to characterize the associations between
various characteristics and eGFR. A multiple regression
model was employed to evaluate the contribution of each
confounding factor to eGFR. Subjects were divided into four
groups based on the stage of eGFR (stage 1, eGFR ≥ 90;
stages 2, 89.9 to 60; stage 3a, 59.9 to 45.0; stage 3b, 44.9
to 30.0; stage 4, <30mL/min/1.73m2) and quartile of serum
bilirubin (Q-1, 0.13–0.50; Q-2, 0.51–0.70; Q-3, 0.71–1.00; Q-4,
1.01–1.97mg/dL), and logistic regression analyses were used
Table 1: Characteristics of various risk factors of the subjects.
Characteristic (𝑁 = 509) Value
Gender male (%) 45.2
Age (years) 79 ± 10
Body mass index† (kg/m2) 21.5 ± 3.9
Smoking status‡ (%) 74.7/2.2/9.8/13.4
Systolic blood pressure (mmHg) 137 ± 27
Diastolic blood pressure (mmHg) 75 ± 15
Antihypertensive medication (%) 56.2
Triglycerides (mg/dL) 82 (61–114)
HDL cholesterol (mg/dL) 55 ± 17
LDL cholesterol (mg/dL) 104 ± 35
Antidyslipidemic medication (%) 8.4
Fasting blood glucose (mg/dL) 151 (132–183)
Antidiabetic medication (%) 43.6
Serum uric acid (mg/dL) 5.5 ± 2.1
Serum creatinine (mg/dL) 1.1 ± 0.9
eGFR (mL/min/1.73m2) 56.0 ± 20.2
CKD stage (1 + 2/3a/3b/4), % 51.5/21.2/14.5/12.8
Serum bilirubin (mg/dL) 0.7 (0.5–1.0)
Cardiovascular disease (%) 40.1
Data are presented as means ± standard deviation. HDL: high-density
lipoprotein; LDL: low-density lipoprotein; eGFR: estimated glomerular fil-
tration rate. †Body mass index was calculated using weight in kilograms
divided by the square of the height in meters. ‡Smoking status: daily con-
sumption (pack) × duration of smoking (year) {never, light (<20 pack⋅year),
moderate (20–39 pack⋅year), and heavy (≥40 pack⋅year)}. Data for
triglycerides, fasting plasma glucose, and serum bilirubin were skewed and
are presented as median (interquartile range) values.
to test significant determinants of CKD serving as the
dichotomous outcome variable. To examine the consistency
of the observed association between serum bilirubin levels
and eGFR, we performed subgroup analyses by age (<80,
≥80 years), medication (such as antihypertensive, antidyslipi-
demic, and antidiabetic agents) (absence, presence), serum
uric acid (first-second tertiles, third tertile), and CVD
(absence, presence), and interaction between serum bilirubin
and the subgroups was analyzed by a general linear model. A
value of 𝑃 < 0.05 was considered significant.
3. Results
3.1. Subject Background Factors of the Subjects. Table 1 shows
the value of background factor of the subjects. The subjects
comprised 230 men aged 77 ± 10 (range, 50–100) years and
279 women aged 81 ± 10 (range, 50–101) years. Mean uric
acid, Cr, and eGFR in the study sample were 5.5 ± 2.1 (SD)
mg/dL, 1.1 ± 0.9mg/dL, and 56.0 ± 20.2mL/min/1.73m2
with 1.0% stage 1, 51.5% stage 2, 21.2% stage 3a, 14.5% stage
3b, and 12.8% stage 4, respectively. Median serum bilirubin
level was 0.7 (interquartile range, 0.5–1.0) mg/dL. Prevalence
of antihypertensive, antidyslipidemic, antidiabetic medi-
cation, and CVD was 56.2%, 8.4%, 43.6%, and 40.1%,
respectively.
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Table 2: Relationship between various risk factors including serum bilirubin and estimated glomerular filtration rate.
Characteristic (𝑁 = 509)
Pearson’s Multiple linear regression analysis
correlation Forced method Stepwise method
𝑟 (𝑃 value) 𝛽 (𝑃 value) 𝛽 (𝑃 value)
Gender (male = 0, female = 1) −0.08 (0.059) −0.11 (0.006) −0.07 (0.032)
Age −0.35 (<0.001) −0.29 (<0.001) −0.27 (<0.001)
Body mass index −0.02 (0.645) −0.03 (0.397) —
Smoking status 0.02 (0.738) −0.06 (0.129) —
Systolic blood pressure 0.05 (0.260) — —
Diastolic blood pressure 0.21 (<0.001) 0.05 (0.174) —
antihypertensive medication −0.18 (<0.001) −0.08 (0.026) −0.09 (0.004)
Triglycerides −0.17 (<0.001) −0.06 (0.152) —
HDL cholesterol 0.14 (0.002) 0.06 (0.077) 0.09 (0.008)
LDL cholesterol 0.11 (0.017) 0.07 (0.057) —
Antidyslipidemic medication 0.00 (0.974) −0.02 (0.573) —
Fasting blood glucose 0.03 (0.501) 0.01 (0.736) —
Antidiabetic medication 0.00 (0.983) −0.04 (0.233) —
Serum uric acid −0.59 (<0.001) −0.53 (<0.001) −0.56 (<0.001)
Serum bilirubin 0.22 (<0.001) 0.12 (<0.001) 0.13 (<0.001)
𝑅
2 — 0.50 (<0.001) 0.49 (<0.001)
𝑟: Pearson’s correlation coefficient; 𝛽: standardized coefficient; 𝑅2: multiple coefficient of determination. Data for triglycerides, fasting plasma glucose, and
serum bilirubin were skewed and log-transformed for analysis.
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Figure 1: Relationship between serum bilirubin and estimated
glomerular filtration rate (eGFR). CKD-EPI equations modified
by a Japanese coefficient: male, Cr ≤ 0.9mg/dL, 141 ×
(Cr/0.9)−0.411 × 0.993age × 0.813; Cr > 0.9mg/dL, 141 ×
(Cr/0.9)−1.209 × 0.993age × 0.813; female, Cr ≤ 0.7mg/dL, 144
× (Cr/0.7)−0.329 × 0.993age × 0.813; Cr > 0.7mg/dL, 144 ×
(Cr/0.7)−1.209 × 0.993age × 0.813. Serum bilirubin was skewed and
log-transformed for analysis.
3.2. Relationship of Risk Factors, including SerumBilirubin and
eGFR. Table 2 shows the relationship between participant
characteristics and eGFR. Serum bilirubin (𝑟 = 0.22, 𝑃 <
0.001) along with age, DBP, prevalence of antihypertensive
medication, TG, HDL-C, LDL-C, and serum uric acid cor-
related significantly with eGFR (Figure 1). Stepwise multiple
regression analysis using eGFR as an objective variable,
adjusted for risk factors as explanatory variables, showed that
serum bilirubin (𝛽 = 0.13, 𝑃 < 0.001) was significantly and
independently associated with eGFR, in addition to gender,
age, prevalence of antihypertensive medication, HDL-C, and
serum uric acid.
3.3. Relationship between Serum Bilirubin Categories and
Risk for Reduced eGFR (Stages 3 + 4 or Stages 3b + 4).
Table 3 shows the odds ratio of renal dysfunction for each
quartile increase in serum bilirubin. eGFR values decreased
significantly and progressively with decreasing serum biliru-
bin. The prevalence of eGFR < 60mL/min/1.73m2 (stages
3 + 4) for each quartile in serum bilirubin was 40.8%
Q-4, 43.2% Q-3, 51.1% Q-2, and 58.9% Q-1, respectively.
ComparedwithQ-4 in serum bilirubin, nonadjusted, age and
gender-adjusted, and multivariate-adjusted odds ratios {95%
confidence interval (CI)} of stages 3 + 4 for Q-1 in serum
bilirubin were 2.08 (1.25–3.44), 1.82 (1.07–3.09), and 1.53
(0.83–2.81), respectively. Moreover, the prevalence of eGFR
< 45mL/min/1.73m2 (stages 3b + 4) for each quartile in
serum bilirubin was 17.6% Q-4, 21.6% Q-3, 27.4% Q-2, and
42.7% Q-1, respectively. Compared with Q-4, nonadjusted,
age and gender-adjusted, and multivariate-adjusted odds
ratios (95% CI) of stages 3b + 4 for Q-1 were 3.50 (1.95–6.23),
3.12 (1.72–5.65), and 3.53 (1.71–7.26), respectively.
3.4. Relationship of Serum Bilirubin and eGFR within Selected
Subgroups. Next, to control potential confounding factors,
the data were further stratified by gender, age, medication
(antihypertensive, antidyslipidemic, and antidiabetic agents),
serum uric acid (first-second tertiles, third tertile), and
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Table 3: Relationship between serum bilirubin categories and risk for reduced eGFR.
Characteristic𝑁 = 509
Quartiles of serum bilirubin (mg/dL)
𝑃 valueQ-4
1.01–1.97
𝑁 = 125
Q-3
0.71–1.00
𝑁 = 125
Q-2
0.51–0.70
𝑁 = 135
Q-1
0.13–0.50
𝑁 = 124
eGFR (mL/min/1.73m2) 59.5 ± 17.9 60.2 ± 18.8 56.0 ± 18.9 48.1 ± 22.9 <0.001
Prevalence of eGFR <60,𝑁 (%) 51 (40.8) 54 (43.2) 69 (51.1) 73 (58.9) 0.018
Nonadjusted OR (95% CI) 1.00 1.10 (0.67–1.82) 1.52 (0.93–2.48) 2.08 (1.25–3.44) 0.018
Age and gender adjusted OR (95% CI) 1.00 1.23 (0.72–2.09) 1.52 (0.91–2.54) 1.82 (1.07–3.09) 0.133
Multivariate adjusted OR (95% CI) 1.00 1.30 (0.70–2.41) 1.48 (0.81–2.72) 1.53 (0.83–2.81) 0.514
Prevalence of eGFR <45,𝑁 (%) 22 (17.6) 27 (21.6) 37 (27.4) 53 (42.7) <0.001
Nonadjusted OR (95% CI) 1.00 1.29 (0.69–2.42) 1.77 (0.97–3.21) 3.50 (1.95–6.25) <0.001
Age and gender adjusted OR (95% CI) 1.00 1.33 (0.70–2.54) 1.71 (0.93–3.14) 3.12 (1.72–5.65) 0.001
Multivariate adjusted OR (95% CI)§ 1.00 1.68 (0.78–3.64) 1.74 (0.83–3.65) 3.53 (1.71–7.26) 0.004
CKD: chronic kidney disease: OR: odds ratio; CI: confidence interval. §Adjusted for all confounding factors in the stepwise method in Table 2 by multiple
logistic regression analysis. Data for triglycerides were skewed and log-transformed for analysis.
Table 4: Relationship between serum bilirubin and estimated
glomerular filtration rate within selected subgroups.
Characteristics (𝑁 = 509) 𝑁 𝛽 (𝑃 value) 𝑃-interaction
Gender
Men 230 0.13 (0.013) 0.923
Women 279 0.14 (0.001)
Age
<80 years 200 0.21 (0.001) 0.075
≥80 years 279 0.10 (0.028)
Medication
Absence 141 0.12 (0.047) 0.670
Presence 368 0.14 (<0.001)
Serum uric acid
First-second tertiles 319 0.18 (<0.001) 0.830
Third tertile 190 0.13 (<0.001)
Cardiovascular disease
Absence 305 0.05 (0.210) 0.020
Presence 204 0.21 (<0.001)
𝛽: standardized coefficient. Medication included antihypertensive, antidys-
lipidemic, and antidiabetic agents. §Adjusted for all confounding factors in
the stepwise method in Table 2 by multiple linear regression analysis.
prevalence of CVD (Table 4). The standardized coefficients
for eGFR were significant in all subgroups other than the
prevalence of CVD, and there were significant interactions
only between the two groups regarding CVD.
4. Discussion
To examine the possible contribution of decreased serum
bilirubin to renal dysfunction among diabetic persons, we
studied the relationship between potential confounding risk
factors including serum bilirubin and eGFR. This study
showed a graded decrease in eGFR with decreasing serum
bilirubin. Individuals with hypobilirubinemia (first quartile
of serum bilirubin, <0.50mg/dL) showed increased risk
for stage 3b CKD (eGFR < 45mL/min/1.73m2). Moreover,
the strength of serum bilirubin level as an independent
determinant of eGFR was similar to those of known factors
such as gender, age, prevalence of antihypertensive medi-
cation, HDL-C, and serum uric acid. To our knowledge,
few epidemiologic studies have quantified the link between
decreased serum bilirubin and renal dysfunction in diabetic
patients. Thus, we think that serum bilirubin levels may be
utilized as a provisional new confounding factor of diabetic
nephropathy that can be measured easily and applied in
medical practice.
Several studies have shown that decreased serum biliru-
bin is a risk factor for the development of CKD among
type 2 diabetic individuals. Inoguchi et al. [15] showed a
lower prevalence of vascular complications as well as reduced
markers of oxidative stress and inflammation in patients
with Gilbert’s syndrome, which is a congenital hyperbiliru-
binemia, and diabetes. A community-based cross-sectional
study in Korea [7] found that total serum bilirubin levels
were negatively correlated with 24-hour proteinuria and
positively associated with eGFR after adjusting for potential
confounding factors in 612 diabetic patients. Fukui et al.
[6] found that serum bilirubin level was independently
and negatively associated with albuminuria in a hospital-
based cross-sectional study in 633 Japanese type 2 diabetic
patients. In addition, it was shown that serum bilirubin
levels were higher in patients without diabetic nephropathy
than in those with diabetic nephropathy. In a longitudinal
cohort study of 12,823 Korean male workers without CKD or
proteinuria at baseline, higher serum direct bilirubin levels
were significantly associated with a lower risk of develop-
ing CKD (eGFR, <60mL/min/1.73m2), even after adjusting
for potential confounding factors [5]. In the single-center
longitudinal observational cohort study of type 2 diabetic
patients, Toya et al. [11] found that higher serum bilirubin
levels, within the normal range, were associated with a lower
risk of progression from microalbuminuria to macroalbu-
minuria. In a hospital-based study of 2,678 US diabetic
outpatients (mean age: 55±18 years), Targher et al. [12] found
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that serum bilirubin levels were negatively associated with
eGFR. However, in that study, no adjustment was made for
potential confounding factors. Longitudinal data from 2,511
type 2 diabetic Japanese patients showed that multivariable-
adjusted odds ratios for progression from microalbuminuria
to macroalbuminuria for the second, third, and fourth quar-
tiles of serum bilirubin levels were 0.89 (95% CI 0.49–1.58),
0.93 (0.47–1.83), and 0.33 (0.13–0.84), respectively. However,
this trend disappeared after adjustment for hemoglobin level
[9]. In our hospital-based sample of 509 individuals, we
found that decreased serum bilirubin levels were significantly
associated with decreased eGFR, and multivariate adjusted-
odds ratio of hypobilirubinemia (0.13–0.50mg/dL) for stage
3b (eGFR < 45mL/min/1.73m2) was 3.53 (1.71–7.26).
The mechanism by which serum bilirubin level is associ-
ated with a lower risk of CKD is not completely understood.
Bilirubin has been described as the most powerful endoge-
nous antioxidant substance in vitro [16] when acting alone
and complexed with serum albumin to serve as a superoxide
scavenger and peroxyl radical trapping antioxidant [17].
Hyperglycemia causes mitochondrial superoxide overpro-
duction in vascular endothelial cells [18]. A recent study in
a rodent model discovered a protective effect of bilirubin
against diabetic nephropathy through inhibition of renal
nicotinamide adenine dinucleotide phosphate- (NADPH-)
dependent superoxide production and both hyperglycemia
and angiotensin-II-induced production of reactive oxygen
species [19]. Taken together, the present results suggest that
bilirubin might have a protective role in the progression
of diabetic nephropathy, particularly in diabetic patients
with greater oxidative stress such as CVD. In our study,
the standardized coefficient for eGFR was significant in the
subgroup with prevalence of CVD, and there were significant
interactions between the two groups regarding CVD.
We must be aware of the limitations to the present study.
First, due to the cross-sectional study design, the present
results are inherently limited in the ability to eliminate causal
relationships between serum bilirubin and eGFR among
diabetic patients. Second, our definition of eGFR is based on a
single assessment of serum creatinine, which may introduce
a misclassification bias. Third, estimating GFR listed as the
CKD-EPI equation tends to be less accurate in subjects with
normal renal function and CKD than GFR when inulin
clearance is used, but is more accurate than serum creatinine
or eGFR using the Modification of Diet in Renal Disease
(MDRD) formula [14]. Fourth, in this study, CKD may
have been misclassified with eGFR > 60mL/min/1.73m2 and
proteinuria as mildly reduced renal function because renal
dysfunction was defined as reduced eGFR irrespective of
the presence or absence of proteinuria. Therefore, the demo-
graphics and referral source may limit generalizability.
5. Conclusion
The present study showed that decreased serum bilirubin
levels are strongly associated with decreased eGFR among
diabetic patients. The underlying mechanism behind this
relationship is unclear, but seems to be independent of tra-
ditional confounding risk factors such as age, hypertension,
and dyslipidemia. For community-dwelling diabetic patients,
prospective population-based studies are needed to investi-
gate the mechanisms underlying this association.
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